CDK4/6 inhibitors in metastatic breast cancer, a comparison of toxicity and efficacy across agents in a real-world dataset

• Published in: Journal of oncology pharmacy practice p. 10781552231163121
• Main Authors: Buller, William, Pallan, Lalit, Chu, Teresa, Khoja, Leila
• Format: Journal Article
• Language: English
• Published: England 01.12.2023
• Subjects: toxicity; Metastatic breast cancer; CDK4/6 inhibitor

CDK4/6 inhibitors (ribociclib, palbociclib and abemaciclib) are 1st line therapy in metastatic breast cancer (MBC). No comparative data exists between agents regarding toxicity or efficacy. A retrospective study was performed at our tertiary referral centre evaluating patients on a CDK4/6 inhibitor...